A subset of CD16-natural killer cells without antibody-dependent cellular cytotoxicity function.
The low affinity IgG receptor, CD16 (Fc gamma RIII), is expressed on almost all peripheral blood natural killer (NK) cells. A small subset of CD3- CD16- CD56+ NK cells, representing less than 1% of peripheral blood lymphocytes, expands during in vivo IL-2 treatment. To analyze this CD16- NK cell subset in more detail, NK clones have been generated. One of them (TNK2) has been used to study the function of these cells in more detail. It is demonstrated that TNK2 exerts normal NK activity and displays large granular lymphocyte morphology. Since this clone lacks CD16 expression, antibody-dependent cellular cytotoxicity cannot be exerted. CD16 monoclonal antibodies fail to induce cytotoxic activity against NK-resistant target cells. These studies reveal that the lack of CD16 detection is not due to the modulation or the stage of activation of these NK cells. TNK2 is representative of this small subset of peripheral blood NK cells, expanded during IL-2 treatment, which does not express Fc gamma RIII and therefore cannot perform antibody-dependent cellular cytotoxicity.
Schubert
J
J
Abteilung Immunologie und Transfusionsmedizin, Medizinische Hochschule Hannover, FRG.
Heiken
H
H
Jacobs
R
R
Delany
P
P
Witte
T
T
Schmidt
R E
RE
D000911:Antibodies, Monoclonal / Q000276:immunology; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology / Q000502:physiology*; D000943:Antigens, Differentiation / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D002460:Cell Line; D002999:Clone Cells; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000276:immunology / Q000502:physiology*; D008214:Lymphocytes / Q000378:metabolism; D010641:Phenotype; D011961:Receptors, Fc / Q000276:immunology; D017452:Receptors, IgG
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D000954:Antigens, Surface; D007376:Interleukin-2; D011961:Receptors, Fc; D017452:Receptors, IgG